Latest Manufacturing Technology News

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.

AML3D will contribute about A$530,000 to a three-year, A$3.89 million research project aimed at qualifying its Wire-Arc Additive Manufacturing technology for aerospace tooling. The project carries no immediate revenue, but could open the door to future production contracts if qualification succeeds.

AdAlta says a 10-year, up to US$120 million agreement between manufacturing partner Oribiotech and an undisclosed commercial-stage biopharmaceutical company validates its choice of IRO automation for future cellular immunotherapies. The deal does not create direct revenue for AdAlta, and its lead asset EW-001 will continue with a separate manufacturing process.

AML3D has secured an initial AU$0.5 million order to manufacture three high-pressure copper-nickel components for US Navy nuclear submarines. The deal moves its Ohio operation from qualification programs into paid production, although delivery, testing and commissioning remain outstanding.

Vitrafy Life Sciences has secured its first US cell and gene therapy foothold by deploying its cryopreservation technology at Charter Medical's Innovation Hub, signalling a strategic expansion into a high-value biopharma segment.

Aurora Labs posted a 36% increase in net loss to $5.1 million for FY2026 despite securing key defence contracts and partnerships. The company is transitioning from R&D to early commercialisation of its micro gas turbine propulsion systems, backed by a $5.5 million capital raise and government grants.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.

NeuroScientific Biopharmaceuticals achieved an 80% clinical response rate in fistulising Crohn’s disease patients treated under the TGA Special Access Scheme, advancing plans for Phase 2 trials and manufacturing scale-up.

Perpetual Resources has validated multiple high-grade tungsten zones at its Paraíba Project in Brazil, underpinning a strategic push into critical minerals with a planned follow-up exploration phase.

Amaero Inc. capped FY2026 with a record A$18.1 million revenue, expanded its production capacity, and landed a A$6.5 million US Department of War contract to develop alternative refractory alloy powders.

Critical Resources Limited has secured independent peer-reviewed validation of its dry supersonic deposition (DSD) cathode technology, confirming a solvent- and binder-free process with promising durability and capacity metrics. This milestone strengthens its licensing prospects as the company advances toward full solid-state battery integration.

IperionX has won up to US$6.6 million from the US Department of War to scale production of ballistic-grade titanium plate and military components, aiming to reduce reliance on imports and strengthen domestic supply chains.